[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uric-acid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uric-acid":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100563933","phase-4-the-effects-of-febuxostat-dose-tapering-in-gout-patients-optimally-controlled-for-5-years-or-more-100563933",false,"NCT06622603","the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More","A Prospective, Multicenter, Randomized Investigator Initiative Clinical Trial Study on the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More","TARGET","* Inclusion Criteria:\n\n  1. Adult gout patients aged ≥19 but \\\u003C80 years.\n  2. Gout patients treated with urate-lowering therapy (either allopurinol or febuxostat monotherapy, or a combination of two agents) for at least the past 5 years.\n  3. Patients who have at least five serum urate level measurements over the past 5 years and meet one of the following criteria:\n\n     All serum urate levels measured in the past 5 years have been maintained below 6.0 mg\u002FdL; or the area under the curve (AUC) of serum urate levels over time for the past 5 years is less than 33.0 mg\u002FdL x year\n  4. Patients without palpable or visible tophi on physical examination (evaluated at pre-defined 18 joint sites and the ears).\n  5. Patients without acute gouty attack or history of nephrolithiasis in the past 12 months\n  6. Patients with an estimated glomerular filtration rate (eGFR) of 60 mL\u002Fmin\u002F1.73m² or higher, based on the Cockcroft-Gault formula.\n  7. Patients who voluntarily provide written informed consent to participate.\n* Exclusion Criteria:\n\n  1. Subjects who continuously require prophylactic low-dose colchicine\u002FNSAIDs.\n  2. Subjects already having taken low-dose urate-lowering agents. The low-dose urate-lowering agents are defined as allopurinol ≤200 mg\u002Fday or febuxostat ≤20 mg\u002Fday. But patients on a combination of low-dose allopurinol and febuxostat are eligible.\n  3. Subjects taking medications that could affect serum uric acid levels and uric acid fractional excretion rates, such as benzbromarone, fenofibrate, loop diuretics, thiazide or thiazide-like diuretics, and losartan.\n  4. Subjects classified as having high-risk alcohol use according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA):\n\n     For men \\\u003C65 years: more than 14 drinks per week or for men ≥65 years or women: more than 7 drinks per week\n  5. Subjects with a history of hypersensitivity to febuxostat or allopurinol\n  6. Subjects with unstable cardiovascular conditions, who require adjustment of urgent their therapy\n  7. Subjects taking mercaptopurine or azathioprine\n  8. Subjects with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n  9. Subjects with moderate or severe liver dysfunction (AST or ALT levels greater than 3 times the upper normal limit)\n  10. Subjects for whom investigators anticipate that a change in a urate-lowering agent dose could present significant risks or that any factor could severely impact drug adherence, complicating study registration.","ALL","19 Years","79 Years",{"count":21,"type":22},59,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to compare the changes in serum urate levels and symptom recurrence after reducing or suspending urate-lowering agents in well-controlled gout patients (the 'after dishes are clean' state in the Dirty Dish hypothesis)\n\nResearchers will compare three randomized groups: the reducing group takes febuxostat 20 mg once daily for 12 months, the discontinuing group takes a placebo once daily for 6 months, followed by febuxostat 20 mg once daily for the next 6 months, and the maintaining group continues their pre-study urate-lowering agents for 12 months, serving as an observational reference group.\n\nDuring the 12-month study period, participants will visit every 3 months for laboratory evaluations including serum urate levels, and for checking symptomatic status using questionnaires and diaries. Additionally, musculoskeletal ultrasonography and serum sample collection will be performed at baseline to study predictors for maintaining serum urate levels \\\u003C7.0 mg\u002FdL after reducing or suspending urate-lowering therapy.",[28,29],"Gout","Uric Acid",[31,32],"Febuxostat","Allopurinol","RECRUITING","2026-04-23",{"date":36,"type":37},"2026-04-29","ACTUAL",{"date":39,"type":37},"2025-09-10",{"date":41,"type":22},"2027-08-19",{"name":43,"class":44},"Seoul National University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":45},"100569296","the-effects-of-endotracheal-suctioning-on-pain-and-serum-markers-100569296","NCT06692400","The Effects of Endotracheal Suctioning on Pain and Serum Markers","The Impact of Endotracheal Suctioning on Pain, Hypoxia, and Oxidative Stress Biomarkers in Intubated Adult ICU Patients: A Controlled Trial","Inclusion Criteria:\n\n* Adults (aged 18 years and older)\n* Current diagnosis of flu, pneumonia, COVID, or sepsis\n* Intubated and receiving mechanical ventilation.\n* Have arterial lines placed\n* Require endotracheal suctioning as part of their care\n\nExclusion Criteria:\n\n* Patients receiving neuromuscular blocking agents\n* Contraindications for blood draws (hemoglobin levels below 8.0 g\u002FdL; Jehovah's Witness)","18 Years",{"count":55,"type":22},110,[57],"NA","The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress.\n\nThe main questions this study aims to answer are:\n\nDoes ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress.\n\nParticipants will:\n\nHave pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning.\n\nProvide demographic information (like age, gender, and diagnosis) from medical records.\n\nThis research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.",[60,61,62,63,64,65,66,67,68,69,29,70,71,72,73],"Intensive Care Unit ICU","Intubation","Critical Illness","Mechanical Ventilation","Pain Measurement","Pain, Procedural","Oxidative Stress","Hypoxia","Biomarkers \u002F Blood","Adult","Sepsis","COVID","Influenza","Pneumonia","2025-05-19",{"date":76,"type":37},"2025-05-21",{"date":78,"type":37},"2025-01-30",{"date":80,"type":22},"2026-04",{"name":82,"class":44},"Loma Linda University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":45},"100511775","phase-3-the-effect-of-allopurinol-on-the-risk-of-cardiovascular-events-in-patients-with-cardiovascular-risk-100511775","NCT05943821","The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk","A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with High and Very High Cardiovascular Risk, Including the Presence of Long-COVID Syndrome.","ALL-VASCOR","Inclusion Criteria:\n\n1. Age: between 40-70 years old.\n2. Giving informed consent to participate in the study.\n3. Serum UA levels above 5 mg\u002Fdl within the last six months before the screening visit.\n4. Meeting at least one of the criteria defining high or very high CV risk includes:\n\n   1. calculated 10-year cardiovascular mortality risk based on SCORE2 \\>2.5% for patients under 50 years old or ≥5% for patients 50 years old or older\n   2. documented occurrence of CV diseases (cerebrovascular disease: ischemic stroke, intracerebral bleeding, TIA; heart failure regardless of the etiology NYHA I - II (without IHD), PAD, atrial fibrillation (de novo or ever)\n   3. diabetes or arterial hypertension complicated by organ damage:\n\n      * increase in vascular stiffness: pulse pressure ≥ 60 mmHg, and\u002For cervicofemoral PWV \\> 10 m\u002Fs;\n      * features of left ventricular hypertrophy on echocardiography or electrocardiography;\n      * increased urine albumin-creatinine ratio (30-300 mg\u002Fg);\n      * ankle-brachial index \\\u003C 0.9.\n\nExclusion Criteria:\n\n1. Taking allopurinol, febuxostat or other hypouricemic drugs.\n2. Contraindications to taking allopurinol.\n3. Pregnant women, breastfeeding or planning pregnancy during the duration of the study.\n4. Hormonal therapy containing oestrogens.\n5. Active cancer process or disease in the last five years, excluding locally malignant tumours.\n6. Uncontrolled hypertension (mean value ≥ 180\u002F110 mmHg seven days before screening visit) in home measurements despite using hypotensive drugs.\n7. 7\\. Renal insufficiency with an eGFR \\\u003C45 ml\u002F min\u002F1.73m2 (according to 2009 CKD-EPI recommendations: stage G3b, G4 and G5).\n8. Hypothyroidism or hyperthyroidism not in a state of euthyroidism.\n9. Confirmed coronary artery disease (defined as prior AMI, revascularization of the myocardium, confirmed presence of atherosclerotic plaques in coronary arteries on imaging studies).\n10. Heart failure in NYHA class III and IV.\n11. Taking preparations: azathioprine, mercaptopurine or cyclosporin. Participation in another clinical trial of a medicinal product or medical device within the last three months or five half-lives, whichever period is longer.","40 Years","70 Years",{"count":94,"type":22},1116,[96],"PHASE3","Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk, excluding ischemic heart disease. This is particularly important due to the high cost of cardiovascular disease treatment and its status as one of the leading causes of death.",[99,29],"Cardiovascular Diseases","2025-01-03",{"date":102,"type":37},"2025-01-06",{"date":104,"type":37},"2023-09-01",{"date":106,"type":22},"2028-07-31",{"name":108,"class":44},"Poznan University of Medical Sciences"]